TCON(Delisted)
TRACON·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 0
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TCON
Tracon Pharmaceuticals, Inc.
A clinical stage biopharmaceutical company that develops novel targeted therapeutics for cancer
4350 La Jolla Village Drive
, Suite 800
, San Diego, CA 92122
--
TRACON Pharmaceuticals, Inc., was incorporated in Delaware on October 28, 2004. The Company is a biopharmaceutical company focused on the development and commercialization of novel targeted therapies for cancer, and leverages a cost-effective, contract research organization (CRO) independent product development platform to collaborate with other life science companies to develop and commercialize innovative products in the United States.
Company Financials
EPS
TCON has released its 2024 Q1 earnings. EPS was reported at -1.33, versus the expected -0.06, missing expectations. The chart below visualizes how TCON has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TCON has released its 2024 Q1 earnings report, with revenue of 100.00K, reflecting a YoY change of NaN%, and net profit of -3.17M, showing a YoY change of 62.75%. The Sankey diagram below clearly presents TCON's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
